The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Immupharma have stated that they wouldn't fund a further phase III themselves - therefore they're actively seeking a partner. The most recent RNS states that discussions with regulatory bodies were underway regarding the design of a new phase III trial. Hopefully a partnership announcement will be made soon!
Ureka / Immupharma and University of Bordeaux now published: Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking - published in Chemical Science. https://pubs.rsc.org/en/content/articlelanding/2019/sc/c9sc02079a#!divAbstract
Lanstead's payments start 1st Sept' - the amount is dependent on an average of SP during 20 days prior to payment day. We are in that zone now therefore most likely to see an RNS to help raise the average price!
Come on Tim, open the doors to that rich vein of positive news flow you spoke about early July.
No-one gets the rationale behind the Incanthera investment - especially after this recent fund raise. The company alleges that they didn't need to raise funds just now!! Tim stated that with the money leftover from trial expenses at end of 2018 (4.9 million) and this new money puts them in a very strong financial position.
Anyone know what monthly cashburn might be - we don't know how much of the 4.9 million is left six months on. It's all a bit vague.
It's at an all time low, however this could be the time to buy! At least for the short term.
I don't know Tim McCarthy but I think he has been the focus for much understandable frustrations, just bear in mind there is a BOD making the decisions, some of which recently have been like ****ing in your own nest!
Nolupus, you have been the realist here and I hold your comments in high regard, however I don't agree with your statement on Lanstead that they are in a win win situation. I watched the recent video on Proactive Investors explaining the mechanics of the Lanstead deal and although the money they pay to Immupharma is relative to the share price they have already received all of their shares and are a major share holder. It is in their interest for the share price to improve.
It is imperative for Immupharma that the share price improves from here to benefit substantially from this deal and in said video TM stated that both companies would not have entered an agreement unless there would be positive news flow to improve share price - that needs to be within the next two months because the Lanstead payments kick-in thereafter and they are dependent on share price. A further phase III trial would need to be successful to gain regulatory approval - to which Tim alluded would not be paid for by Immupharma, therefore it is possible a partnership deal is in final discussions because this is the only piece of news IMHO which could move the share price substantially.
Whilst negotiating the subscription deal I'm assuming Lanstead had access to information we PI's aren't privy to - why else would they invest 2.66 million?
The amount of monies payable to immupharma through the subscription is dependent on the share price being higher or lower than a base price of 13.33p. The payments are due to commence in a couple of months, therefore I'm expecting positive news flow from Immupharma over the next few weeks in order to maintain and improve share price otherwise the subscription payments will be lower than anticipated.
Firstly, let's see proven efficacy through the extension study results, Immupharma would then have a stronger hand. They are currently engaged with potential partners, therefore you could assume they have already had some positive feedback from the extension study. Up to ten weeks from now will perhaps answer a lot of questions!
For me watching and reading about this share for a year or so I'm thinking that the urgency needs to be getting a deal done with a partner, and that means one with deep pockets - not with the likes of Incanthera who are just as cash strapped as Immupharma. By the company's own admission they will have to conduct another Phase III study for which there isn't enough money in the pot! The extension trial nor MAP will be enough to gain approval with FDA, however some positive findings will boost SP which could help with a further cash raising. I'm holding for now!